https://www.selleckchem.com/pr....oducts/sb-204990.htm
The latest SARS-CoV-2 variant of concern Omicron, with its immune escape from therapeutic anti-Spike monoclonal antibodies and vaccine-elicited sera, demonstrates the continued relevance of COVID19 convalescent plasma (CCP) therapies. Lessons learnt from previous usage of CCP suggests focusing on outpatients and immunocompromised recipients, with high neutralizing antibody (nAb) titer units. In this analysis we systematically reviewed Omicron neutralizing plasma activity data, and found that approximately 50% (426/911) of CCP from unv
Curtir
Comentario
Compartilhar
